🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Ind-Swift Laboratories Limited INDSWFTLAB NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.indswiftlabs.com
Company Profile ↓
₹230.41
+118.11% 1Y
Mkt Cap₹2,000.80 Cr
P/E6.54
P/B1.43
52W High₹246.44
52W Low₹88.15
Book Value₹159.38
EPS (TTM)₹35.21

Company Overview

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company exports its products. Ind-Swift Laboratories Limited was incorporated in 1995 and is based in Manimajra, India.

Why Investors Should Care

Reasonable Valuation

Trades at a P/E of 6.5, below the sector median of 40.0.

Recent Developments

  • Mar 2026 Revenue of ₹641.29 Cr (+11.7% YoY); net profit ₹41.42 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +11.7%, earnings -83.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR -19.0%, profit CAGR -4.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-19.01%
1 Year:11.68%

Compounded Profit Growth

5 Years:-4.53%
1 Year:-83.47%

Stock Price Performance

1 Year:+118.11%
6 Months:+152.50%
3 Months:+58.46%
1 Month:+42.37%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 90% of range
₹88.15 ₹246.44
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)69.15 · Neutral
Price Performance
1M+42.37%
3M+58.46%
6M+152.50%
1Y+118.11%
Valuation vs Sector

P/E of 6.54 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -19.0% CAGR over 5 years.
  • Earnings shrank at -4.5% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
6.54
Industry PE
39.97
Forward P/E est.
13.08
PEG Ratio
-
Book Value
₹159.38
Price to Book
1.43
P/S
3.22
EV/EBITDA
34.66
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-19.01%
Profit 5Y
-4.53%
Revenue (YoY)
11.68%
Earnings (YoY)
-83.47%

Profitability & Returns

ROCE
3.56%
ROE
2.99%
ROA
2.47%
Profit Margin
6.46%
Op Margin
2.26%
Gross Margin
55.96%
EPS (Latest Qtr)
₹1.76
EPS (TTM)
₹35.21

Balance Sheet & Liquidity

Debt/Equity
1.48
Quick Ratio
3.22
Current Ratio
3.80
Debt
₹20.50 Cr
Total Assets
₹1,673.35 Cr
Current Assets
₹976.75 Cr
Working Capital
₹719.47 Cr

Ownership

Promoter Holding
59.28%
Chg in Prom Hold
-0.16%
FII / Inst Holding
4.61%
Chg in FII Hold
-9.27%

Financial Snapshot

Enterprise Value
₹2,000.80 Cr
Total Revenue (TTM)
₹641.29 Cr
EBITDA
₹81.06 Cr
Free Cash Flow
₹-157.60 Cr
Operating Cash Flow
₹-69.88 Cr
Shares Outstanding
₹8.68 Cr
Gross Margin
55.96%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 INDSWFTLAB Ind-Swift Laboratories Limited NSEPHARMA 230.41 6.54 ₹2,000.80 Cr 0.00% 3.56% 2.99% -19.01% -4.53%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 304.00 Cr310.00 Cr290.00 Cr288.00 Cr529.00 Cr33.00 Cr-128.80 Cr142.37 Cr153.00 Cr152.64 Cr150.85 Cr169.79 Cr
Cost of Revenue -------61.67 Cr57.06 Cr-77.65 Cr70.24 Cr61.47 Cr
Gross Profit -------67.13 Cr85.30 Cr-74.99 Cr80.61 Cr108.31 Cr
Operating Expenses 241.00 Cr250.00 Cr224.00 Cr236.00 Cr437.00 Cr43.00 Cr-79.59 Cr97.16 Cr149.00 Cr80.50 Cr85.27 Cr95.86 Cr
Operating Income 55.00 Cr46.00 Cr53.00 Cr38.00 Cr71.00 Cr-10.00 Cr--12.46 Cr-11.86 Cr-3.00 Cr-5.50 Cr-4.66 Cr12.45 Cr
EBITDA 64.00 Cr60.00 Cr66.00 Cr52.00 Cr91.00 Cr-10.00 Cr-9.26 Cr-4.42 Cr4.00 Cr19.34 Cr25.90 Cr20.57 Cr
Interest Expense 22.00 Cr20.00 Cr21.00 Cr21.00 Cr3.00 Cr09.94 Cr10.03 Cr68.89 L1.00 Cr2.01 Cr67.37 L-
Pretax Income 16.00 Cr32.00 Cr39.00 Cr24.00 Cr527.00 Cr1.00 Cr--6.58 Cr230.46 Cr10.00 Cr10.34 Cr16.39 Cr11.96 Cr
Tax Provision 40.80 Cr14.40 Cr7.02 Cr4.56 Cr31.62 Cr-3.00 L--1.08 Cr8.19 Cr1.70 Cr2.30 Cr6.87 Cr-3.15 Cr
Net Income -25.00 Cr17.00 Cr32.00 Cr19.00 Cr494.00 Cr1.00 Cr--5.49 Cr222.27 Cr9.00 Cr7.99 Cr9.54 Cr15.11 Cr
Diluted EPS -4.252.925.363.2983.550.16--0.8231.241.450.961.131.76

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 660.00 Cr653.00 Cr716.00 Cr765.00 Cr757.00 Cr780.00 Cr891.00 Cr-1,207.31 Cr1,709.15 Cr574.24 Cr641.29 Cr
Cost of Revenue --------766.86 Cr996.71 Cr287.95 Cr282.45 Cr
Gross Profit --------440.45 Cr712.44 Cr286.29 Cr358.84 Cr
Operating Expenses 571.00 Cr546.00 Cr610.00 Cr631.00 Cr630.00 Cr635.00 Cr709.00 Cr-258.93 Cr469.99 Cr317.63 Cr344.35 Cr
Operating Income 5.00 Cr22.00 Cr18.00 Cr47.00 Cr22.00 Cr54.00 Cr96.00 Cr-181.52 Cr242.45 Cr-31.34 Cr14.49 Cr
EBITDA 89.00 Cr107.00 Cr106.00 Cr134.00 Cr126.00 Cr144.00 Cr183.00 Cr-230.28 Cr776.43 Cr285.20 Cr81.06 Cr
Interest Expense 117.00 Cr106.00 Cr88.00 Cr28.00 Cr92.00 Cr107.00 Cr100.00 Cr-86.39 Cr97.80 Cr2.92 Cr1.40 Cr
Pretax Income -143.00 Cr-83.00 Cr-55.00 Cr36.00 Cr50.00 Cr-20.00 Cr18.00 Cr-86.52 Cr598.22 Cr257.80 Cr49.05 Cr
Tax Provision 24.31 Cr24.07 Cr15.95 Cr14.04 Cr21.00 Cr-1.40 Cr21.06 Cr-38.69 Cr58.98 Cr7.27 Cr7.73 Cr
Net Income -119.00 Cr-59.00 Cr-39.00 Cr22.00 Cr29.00 Cr-21.00 Cr-3.00 Cr-47.60 Cr538.75 Cr250.48 Cr41.42 Cr
Diluted EPS -29.14-14.33-8.754.856.09-3.59-0.53-4.28-4.2891.1835.21-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 2,244.00 Cr2,215.00 Cr2,138.00 Cr2,023.00 Cr1,924.00 Cr1,870.00 Cr1,818.00 Cr-1,824.06 Cr1,460.43 Cr1,438.34 Cr1,673.35 Cr
Current Assets --------1,164.52 Cr959.46 Cr865.35 Cr976.75 Cr
Cash & Equivalents --------18.20 Cr477.81 Cr412.04 Cr429.85 Cr
Inventory --------438.60 Cr74.55 Cr114.18 Cr147.93 Cr
Receivables --------505.32 Cr312.97 Cr164.52 Cr198.55 Cr
Total Liabilities --------1,142.13 Cr648.37 Cr265.37 Cr289.38 Cr
Current Liabilities --------371.09 Cr432.97 Cr220.58 Cr257.29 Cr
Long Term Debt --------752.60 Cr198.74 Cr25.71 Cr12.11 Cr
Total Debt 1,413.00 Cr1,457.00 Cr1,242.00 Cr1,083.00 Cr1,148.00 Cr1,031.00 Cr1,005.00 Cr-862.10 Cr216.80 Cr40.86 Cr20.50 Cr
Total Equity 595.00 Cr518.00 Cr531.00 Cr553.00 Cr588.00 Cr641.00 Cr604.00 Cr-681.93 Cr812.08 Cr1,173.00 Cr1,384.02 Cr
Shares Outstanding --------5.91 Cr5.91 Cr6.06 Cr8.68 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 98.00 Cr79.00 Cr96.00 Cr73.00 Cr-64.00 Cr125.00 Cr135.00 Cr-194.62 Cr-186.98 Cr-28.69 Cr-69.88 Cr
Investing Cash Flow -35.00 Cr-29.00 Cr-31.00 Cr-17.00 Cr-12.00 Cr-9.00 Cr-10.00 Cr--13.37 Cr-27.15 Cr-113.13 Cr-72.68 Cr
Financing Cash Flow -64.00 Cr-48.00 Cr-69.00 Cr-62.00 Cr100.00 Cr-133.00 Cr-124.00 Cr--185.66 Cr657.35 Cr72.42 Cr141.81 Cr
Capital Expenditure -39.00 Cr-30.00 Cr-33.00 Cr-21.00 Cr-15.00 Cr-11.00 Cr-4.00 Cr--12.77 Cr-73.01 Cr-64.41 Cr-87.72 Cr
Free Cash Flow 59.00 Cr49.00 Cr63.00 Cr52.00 Cr-79.00 Cr114.00 Cr131.00 Cr-181.85 Cr-259.99 Cr-93.10 Cr-157.60 Cr
Net Change in Cash -1.00 Cr3.00 Cr-4.00 Cr-6.00 Cr23.00 Cr-17.00 Cr1.00 Cr--4.41 Cr443.22 Cr-69.39 Cr-75.27 L

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------36.5%41.7%49.9%56.0%
Operating Margin % 0.8%3.4%2.5%6.1%2.9%6.9%10.8%-15.0%14.2%-5.5%2.3%
Net Margin % -18.0%-9.0%-5.4%2.9%3.8%-2.7%-0.3%-3.9%31.5%43.6%6.5%
ROE % -20.0%-11.4%-7.3%4.0%4.9%-3.3%-0.5%-7.0%66.3%21.4%3.0%
ROCE % --------12.5%23.6%-2.6%1.0%

Shareholding Pattern

Insiders
59.28%
Institutions
4.61%
Public Float
11.33%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for INDSWFTLAB

Google News Fri, 10 Jul 2026

Ind-Swift Laboratories Limited | INDSWFTLAB.NS Stock Price & Real-time Quotes - finance.biggo.com

<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE1KT1JlZkdCWUttRkluUVBaQ1JCSnFPU0J1Q0dYbWt0dDEzQndGa01OWm9WeWt4dGlHcEFraUlScFZfRjVjWTNQVjRYTjIzOGdJSUN0QlZqbUs?oc=5" target="_blank">Ind-Swift Laboratories Limited | INDSWFTLAB.NS S…

Google News Sat, 31 Jan 2026

Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) Shares Bounce 29% But Its Business Still Trails The Market - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi-AFBVV95cUxNN0JJM3JmSko3bzBmNWtiUHc4WV91NVNlMHBIZjh1bEdGM3ZGRTBIMkZYeWR5bGtCU0VvNVJXOTM0UE42WXNFUE5mUTNPd0lzYlZVdTJxdTBqOGhYUUYydENNQ3RWUjE0cVBPQS1rRkd4U1dVWkcwa2c2UFQ5S3kxTC12YnExR0dlSnRWN3…

Google News hu, 09 Jul 2026

Ind-Swift Laboratories Limited announced that it expects to receive INR 343 million in funding - marketscreener.com

<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxOaDNIYk51SnJZbW8yVy1YYkxVb0Z5SDZ3b3ZGVnJUYmNfb1N0cXBuWENYUk9tdHZkNjRPOGw1aFZFTkxHbnZpdGRXYVV0NXFMMmZlZXd6Mnk4ZXJ6bVJZTXBpMTFlZWxUbFN6LUpLUlZfNjcxS2tDS3FycFFiZ2kwd2F2bEplRXhaTFlSaU…

Google News Fri, 06 Feb 2026

INDSWFTLAB Share Price Today - Ind-Swift Laboratories Stock Analysis - Equitypandit

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE5QWFNXRXhfdDJ3a0pJWDFPWVNGbmlHM2FtRnlUS1g4c1ZrYkFVOE9rblowWm1kSnRmYXBXUjZTMFhiNkl6OVYzSERuTkloUGNVX3FMRGFfcEZiWFFlTHE5cQ?oc=5" target="_blank">INDSWFTLAB Share Price Today - Ind-Sw…

Google News Wed, 14 Jan 2026

Ind-Swift Laboratories (NSE:INDSWFTLAB) delivers shareholders decent 16% CAGR over 3 years, surging 13% in the last week alone - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxPOXhDWW1lWTB6aFRwUHhhSWtJU2tPcFpCb2ZzNlRFQlk2UHJBdlZ0QWUxVE14TGNqc2QtTEctX0NBMnR1b0RxUGVHb010bFBnTDlZeHJGYnRSWEQzVThVOEFyZ2Z1d1ZIVnFILUlHRFRLZ1ZPWEowenhiT2MyQVQ1eVpmNVJqVTdXaGRHWT…

Google News Mon, 06 Oct 2025

Ind-Swift Laboratories Ltd - Equitypandit

<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE52VjNVWkJVUTFaSkpzTVRYV1h5VDdEbVpwdS13alpZZkxkZFY2STNQUFJJejZIejc4Mkl2SFlqekx2djdHTG83UTRSWUdGaVpnQzlnZmRLd1IwTmtMUTVTdkVQc2FuUQ?oc=5" target="_blank">Ind-Swift Laboratories Ltd</a…

INDSWFTLAB — Frequently Asked Questions

What is the current share price of Ind-Swift Laboratories Limited (INDSWFTLAB)?

As of 2026-07-15 09:52 IST, Ind-Swift Laboratories Limited (INDSWFTLAB) trades at ₹230.41 on NSE. Its 52-week range is ₹88.15 to ₹246.44.

What is the market capitalisation of INDSWFTLAB?

Ind-Swift Laboratories Limited (INDSWFTLAB) has a market capitalisation of ₹2,000.80 Cr on NSE.

What is the P/E ratio of INDSWFTLAB?

INDSWFTLAB trades at a trailing price-to-earnings (P/E) ratio of 6.54. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 1.43.

What is the return on equity (ROE) of INDSWFTLAB?

INDSWFTLAB has a return on equity (ROE) of 2.99%. Its return on capital employed (ROCE) is 3.56%.

Is INDSWFTLAB a good stock to buy?

This page provides a data-driven analysis of Ind-Swift Laboratories Limited (INDSWFTLAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space